ArticleFrontiers in oncology2025
Unmasking recurrent melena as the initial presentation of metastatic prostate cancer: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer, a common malignancy in the male population, is typically characterized by urinary symptoms, such as urinary obstruction and frequency. This report presents a rare case of metastatic prostate cancer that initially manifested with recurrent melena. Case presentation: A 70-year-old man with recurrent melena was admitted to the hospital. Laboratory workups revealed significant pancytopenia, as well as highly elevated serum prostate-specific antigen (PSA) concentrations. However, both upper gastrointestinal endoscopy and colonoscopy found no abnormal bleeding lesions. Further positron emission tomography/computed tomography (PET/CT) examination and pathological results from the bone marrow and prostate gland confirmed the diagnosis of prostate cancer and bone metastasis. After androgen deprivation therapy (goserelin) along with an androgen receptor antagonist (darolutamide), the patient's serum total PSA level declined drastically to 0.01ng/ml, accompanied by an improvement in pancytopenia. During follow-up, he reported significant symptomatic improvement, such as the cessation of melena. Conclusion: When encountering male patients with recurrent melena as the initial presentation, clinicians should be vigilant about the possibility of metastatic prostate cancer. Moreover, a comprehensive evaluation based on multimodality evidence and multidisciplinary management can inform an individualized therapeutic plan for prostate cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.